NCT07464925 2026-03-20
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
Tetragon Biosciences Ltd
Phase 1 Not yet recruiting
Tetragon Biosciences Ltd
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
NYU Langone Health
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
VA Office of Research and Development
Neonc Technologies, Inc.
Medical College of Wisconsin
Suzhou Maximum Bio-tech Co., Ltd.